Pharmacological Treatment for Sleep Apnea

ABSTRACT

The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.

Priority is claimed to U.S. patent application Ser. No. 10/016,901,filed Dec. 14, 2001, which claims priority to U.S. patent applicationSer. No. 09/622,823, filed Aug. 23, 2000, now U.S. Pat. No. 6,331,536issued Dec. 18, 2001, which claims priority International Patent Appl.No. PCT/US99/04347, filed Feb. 26, 1999, which claims priority to U.S.Prov. Patent Appl. No. 60/076,216, all of which are incorporated hereinby reference in their entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention generally relates to methods for the pharmacologicaltreatment of breathing disorders and, more specifically, to theadministration of agents or compositions having serotonin-relatedreceptor activity for the alleviation of sleep apnea (central andobstructive) and other sleep-related breathing disorders.

2. Related Technology

Over the past several years much effort has been devoted to the study ofa discrete group of breathing disorders that occur primarily duringsleep with consequences that may persist throughout the waking hours inthe form of sleepiness, thereby manifesting itself into substantialeconomic loss (e.g., thousands of lost man-hours) or employment safetyfactors (e.g., employee non-attentiveness during operation ofheavy-machinery). Sleep-related breathing disorders are characterized byrepetitive reduction in breathing (hypopnea), periodic cessation ofbreathing (apnea), or a continuous or sustained reduction inventilation.

In general sleep apnea is defined as an intermittent cessation ofairflow at the nose and mouth during sleep. By convention, apneas of atleast 10 seconds in duration have been considered important, but in mostindividuals the apneas are 20-30 seconds in duration and may be as longas 2-3 minutes. While there is some uncertainty as to the minimum numberof apneas that should be considered clinically important, by the timemost individuals come to attention of the medical community they have atleast 10 to 15 events per hour of sleep.

Sleep apneas have been classified into three types: central,obstructive, and mixed. In central sleep apnea the neural drive to allrespiratory muscles is transiently abolished. In obstructive sleepapneas, airflow ceases despite continuing respiratory drive because ofocclusion of the oropharyngeal airway. Mixed apneas, which consist of acentral apnea followed by an obstructive component, are a variant ofobstructive sleep apnea. The most common type of apnea is obstructivesleep apnea.

Obstructive sleep apnea syndrome (OSAS) has been identified in as manyas 24% of working adult men and 9% of similar women, with peakprevalence in the sixth decade. Habitual heavy snoring, which is analmost invariant feature of OSAS, has been described in up to 24% ofmiddle aged men, and 14% of similarly aged women, with even greaterprevalence in older subjects.

Obstructive sleep apnea syndrome's definitive event is the occlusion ofthe upper airway, frequently at the level of the oropharynx. Theresultant apnea generally leads to a progressive-type asphyxia until theindividual is briefly aroused from the sleeping state, thereby restoringairway patency and thus restoring airflow.

An important factor that leads to the collapse of the upper airway inOSAS is the generation of a critical subatmospheric pressure during theact of inspiration that exceeds the ability of the airway dilator andabductor muscles to maintain airway stability. Sleep plays a crucialrole by reducing the activity of the muscles of the upper airwaysincluding the dilator and abductor muscles.

In most individuals with OSAS the patency of the airway is alsocompromised structurally and is therefore predisposed to occlusion. In aminority of individuals the structural compromise is usually due toobvious anatomic abnormalities, i.e, adenotonsillar hypertrophy,retrognathia, or macroglossia. However, in the majority of individualspredisposed to OSAS, the structural abnormality is simply a subtlereduction in airway size, i.e., “pharyngeal crowding.” Obesity alsofrequently contributes to the reduction in size seen in the upperairways. The act of snoring, which is actually a high-frequencyvibration of the palatal and pharyngeal soft tissues that results fromthe decrease in the size of the upper airway lumen, usually aggravatesthe narrowing via the production of edema in the soft tissues.

The recurrent episodes of nocturnal asphyxia and of arousal from sleepthat characterize OSAS lead to a series of secondary physiologic events,which in turn give rise to the clinical complications of the syndrome.The most common manifestations are neuropsychiatric and behavioraldisturbances that are thought to arise from the fragmentation of sleepand loss of slow-wave sleep induced by the recurrent arousal responses.Nocturnal cerebral hypoxia also may play an important role. The mostpervasive manifestation is excessive daytime sleepiness. OSAS is nowrecognized as a leading cause of daytime sleepiness and has beenimplicated as an important risk factor for such problems as motorvehicle accidents. Other related symptoms include intellectualimpairment, memory loss, personality disturbances, and impotence.

The other major manifestations are cardiorespiratory in nature and arethought to arise from the recurrent episodes of nocturnal asphyxia. Mostindividuals demonstrate a cyclical slowing of the heart during theapneas to 30 to 50 beats per minute, followed by tachycardia of 90 to120 beats per minute during the ventilatory phase. A small number ofindividuals develop severe bradycardia with asystoles of 8 to 12 secondsin duration or dangerous tachyarrhythmias, including unsustainedventricular tachycardia. OSAS also aggravates left ventricular failurein patients with underlying heart disease. This complication is mostlikely due to the combined effects of increased left ventricularafterload during each obstructive event, secondary to increased negativeintrathoracic pressure, recurrent nocturnal hypoxemia, and chronicallyelevated sympathoadrenal activity.

Central sleep apnea is less prevalent as a syndrome than OSAS, but canbe identified in a wide spectrum of patients with medical, neurological,and/or neuromuscular disorders associated with diurnal alveolarhypoventilation or periodic breathing. The definitive event in centralsleep apnea is transient abolition of central drive to the ventilatorymuscles. The resulting apnea leads to a primary sequence of eventssimilar to those of OSAS. Several underlying mechanisms can result incessation of respiratory drive during sleep. First are defects in themetabolic respiratory control system and respiratory neuromuscularapparatus. Other central sleep apnea disorders arise from transientinstabilities in an otherwise intact respiratory control system.

Many healthy individuals demonstrate a small number of central apneasduring sleep, particularly at sleep onset and in REM sleep. These apneasare not associated with any physiological or clinical disturbance. Inindividuals with clinically significant central sleep apnea, the primarysequence of events that characterize the disorder leads to prominentphysiological and clinical consequences. In those individuals withcentral sleep apnea alveolar hypoventilation syndrome, daytimehypercapnia and hypoxemia are usually evident and the clinical pictureis dominated by a history of recurrent respiratory failure,polycythemia, pulmonary hypertension, and right-sided heart failure.Complaints of sleeping poorly, morning headache, and daytime fatigue andsleepiness are also prominent. In contrast, in individuals whose centralsleep apnea results from an instability in respiratory drive, theclinical picture is dominated by features related to sleep disturbance,including recurrent nocturnal awakenings, morning fatigue, and daytimesleepiness.

Currently, the most common and most effective treatment, for adults withsleep apnea and other sleep-related breathing disorders are mechanicalforms of therapy that deliver positive airway pressure (PAP). Under PAPtreatment, an individual wears a tight-fitting plastic mask over thenose when sleeping. The mask is attached to a compressor, which forcesair into the nose creating a positive pressure within the patient'sairways. The principle of the method is that pressurizing the airwaysprovides a mechanical “splinting” action, which prevents airway collapseand therefore, obstructive sleep apnea. Although an effectivetherapeutic response is observed in most patients who undergo PAPtreatment, many patients cannot tolerate the apparatus or pressure andrefuse treatment. Moreover, recent covert monitoring studies clearlydemonstrate that long-term compliance with PAP treatment is very poor.

A variety of upper airway and craniofacial surgical procedures have beenattempted for treatment of OSAS. Adenotonsillectomy appears to be aneffective cure for OSAS in many children, but upper airway surgery israrely curative in adult patients with OSAS. Surgical “success” isgenerally taken to be a 50% reduction in apnea incidence and there areno useful screening methods to identify the individuals that wouldbenefit from the surgery versus those who would not derive a benefit.

Pharmacological treatments of several types have been attempted inpatients with sleep apnea but, thus far, none have proven to begenerally useful. A recent systematic review of these attempts isprovided by Hudgel [J. Lab. Clin. Med., 126:13-18 (1995)]. A number ofcompounds have been tested because of their expected respiratorystimulant properties. These include (1) acetazolamide, a carbonicanhydrase inhibitor that produced variable improvement in individualswith primary central apneas but caused an increase in obstructiveapneas, (2) medroxyprogesterone, a progestin that has demonstrated noconsistent benefit in OSAS, and (3) theophylline, a compound usuallyused for the treatment of asthma, which may benefit patients withcentral apnea but appears to be of no use in adult patients withobstructive apnea.

Other attempted pharmacological treatment includes the administration ofadenosine, adenosine analogs and adenosine reuptake inhibitors (U.S.Pat. No. 5,075,290). Specifically, adenosine, which is a ubiquitouscompound within the body and which levels are elevated in individualswith OSAS, has been shown to stimulate respiration and is somewhateffective in reducing apnea in an animal model of sleep apnea.

Other possible pharmacological treatment options for OSAS include agentsthat stimulate the brain activity or are opioid antagonists.Specifically, since increased cerebral spinal fluid opioid activity hasbeen identified in OSAS, it is a logical conclusion that centralstimulants or opioid antagonists would be a helpful treatment of OSAS.In reality, doxapram, which stimulates the central nervous system andcarotid body chemoreceptors, was found to decrease the length of apneasbut did not alter the average arterial oxygen saturation in individualswith obstructive sleep apnea. The opioid antagonist naloxone, which isknown to stimulate ventilation was only slightly helpful in individualswith obstructive sleep apnea.

Because OSAS is strongly correlated with the occurrence of hypertension,agents such as angiotensin-converting enzyme (ACE) inhibitors may be ofbenefit in treating OSAS individuals with hypertension but this does notappear to be a viable treatment for OSAS itself.

Finally, several agents that act on neurotransmitters andneurotransmitter systems involved in respiration have been tested inindividuals with OSAS. Most of these compounds have been developed asanti-depressant medications that work by increasing the activity ofmonoamine neurotransmitters including norepinephrine, dopamine, andserotonin. Protriptyline, a tricyclic anti-depressant, has been testedin several small trials with variable results and frequent andsignificant side effects. As serotonin may promote sleep and stimulaterespiration, tryptophan, a serotonin precursor and selective serotoninreuptake inhibitors have been tested in individuals with OSAS. While apatent has been issued for the use of the serotonin reuptake inhibitor,fluoxetine (U.S. Pat. No. 5,356,934), initial evidence suggests thatthese compounds may yield measurable benefits in only approximately 50%of individuals with OSAS. Therefore in view of the fact that the onlyviable treatment for individuals suffering from sleep-related breathingdisorders is a mechanical form of therapy (PAP) for which patientcompliance is low, and that hopes for pharmacological treatments haveyet to come to fruition, there remains a need for simplepharmacologically-based treatments that would offer benefits to a broadbase of individuals suffering from a range of sleep-related breathingdisorders. There also remains a need for a viable treatment ofsleep-related breathing disorders that would lend itself to a high rateof patient compliance.

SUMMARY OF THE INVENTION

The invention is directed to providing pharmacological treatments forthe prevention or amelioration of sleep-related breathing disorders.

The present invention is directed to methods for the prevention oramelioration of sleep-related breathing disorders, the method comprisingthe administration of an effective dose of serotonin receptor antagonistto a patient in need of such therapy.

The present invention is also directed to methods comprising theadministration of a combination of serotonin receptor antagonists forthe prevention or amelioration of sleep-related breathing disorders. Thecombination of serotonin receptor antagonists may be directed to asingle serotonin receptor subtype or to more than one serotonin receptorsubtype.

The present invention is further directed to methods comprising theadministration of a combination of serotonin receptor antagonists inconjunction with a combination of serotonin receptor agonists for theprevention or amelioration of sleep-related breathing disorders. Thecombination of serotonin receptor antagonists as well as the combinationof receptor agonist may be directed to a single serotonin receptorsubtype or to more than one serotonin receptor subtype.

The present invention is also directed to methods comprising theadministration of a combination of serotonin receptor antagonists inconjunction with a α₂ adrenergic receptor subtype antagonist for theprevention or amelioration of sleep-related breathing disorders. Thecombination of serotonin receptor antagonists may be directed to asingle serotonin receptor subtype or to more than one serotonin receptorsubtype.

Routes of administration for the foregoing methods may be by anysystemic means including oral, intraperitoneal, subcutaneous,intravenous, intramuscular, transdermal, or by other routes ofadministration. Osmotic mini-pumps and timed-released pellets or otherdepot forms of administration may also be used. The only limitationbeing that the route of administration results in the ultimate deliveryof the pharmacological agent to the appropriate receptor.

Sleep-related breathing disorders include, but are not limited to,obstructive sleep apnea syndrome, apnea of prematurity, congenitalcentral hypoventilation syndrome, obesity hypoventilation syndrome,central sleep apnea syndrome, Cheyne-Stokes respiration, and snoring.

A serotonin receptor antagonist can be used in its free base form or asa quaternary ammonium salt form. The quaternization of these serotoninreceptor antagonists occurs by conversion of tertiary nitrogen atom intoa quaternary ammonium salt with reactive alkyl halides such as, forexample, methyl iodide, ethyl iodide, or various benzyl halides. Somequaternary forms of a serotonin antagonist, specifically, methylatedzatosetron, has been shown to lack the ability to cross the blood-brainbarrier (Gidda et al., J. Pharmacol. Eyp. Ther. 273:695-701 (1995)), andthus only works on the peripheral nervous system. A serotonin receptorantagonist is defined by the chemical compound itself and one of itspharmaceutically acceptable salts.

Exemplary serotonin receptor antagonists include, but are not limitedto, the free base form or a quaternized form of zatosetron, tropisetron,dolasetron, hydrodolasetron, mescaline, oxetorone, homochlorcyclizine,perlapine, ondensetron (GR38032F), ketanserin, loxapine, olanzapine,chlorpromazine, haloperidol, r (+) ondensetron, cisapride, norcisapride,(+) cisapride, (−) cisapride, (+) norcisapride, (−) norcisapride,desmethylolanzapine, 2-hydroxymethylolanzapine,1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime,risperidone, cyproheptadine, clozapine, methysergide, granisetron,mianserin, ritanserin, cinanserin, LY-53,857, metergoline, LY-278,584,methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557,3-tropanyl-indole-3-carboxylate, 3-tropanyl-indole-3-carboxylatemethiodide, and other serotonin receptor antagonists and theirquaternized forms or one of its pharmaceutically acceptable salts.

Exemplary serotonin receptor agonists include, but are not limited to8-OH-DPAT, sumatriptan, L694247(2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine),buspirone, aInitidan, zalospirone, ipsapirone, gepirone, zolmitriptan,risatriptan, 311C90, α-Me-5-HT, BW723C86(1-[5(2-thienylmethoxy)-1H-3-indolyl[propan-2-amine hydrochloride), andMCPP (m-chlorophenylpiperazine). A serotonin receptor agonist is definedby the chemical compound itself and one of its pharmaceuticallyacceptable salts.

Exemplary α₂ adrenergic receptor antagonist include, but are not limitedto phenoxybenzamine, phentolamine, tolazoline, terazosine, doxazosin,trimazosin, yohimbine, indoramin, ARC239, and prazosin or one of itspharmaceutically acceptable salts.

Exemplary selective serotonin reuptake inhibitors include, but are notlimited to, fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram,norfluoxetine, r(−) fluoxetine, s(+) fluoxetine, demethylsertraline,demethylcitalopram, venlafaxine, milnacipran, sibutramine, nefazodone,R-hydroxynefazodone, (−)venlafaxine, and (+) venlafaxine. A selectiveserotonin reuptake inhibitor is defined by the chemical compound itselfand one of its pharmaceutically acceptable salts.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the effect of serotonin antagonist GR38032F(ondensetron) on the rate of apneas per hour of non-rapid eye movement(NREM) sleep as compared to control. Each data point on the figurerepresents the mean±the standard error for 9 rats (p=0.007 versuscontrol).

FIG. 2 shows the effect of the serotonin antagonist GR38032F(ondensetron) on the percentage of total recording time spent in NREMsleep as compared to control. Each data point represents the mean±thestandard error for 9 rats (p=0.0001 versus control).

FIG. 3 shows the effect of the serotonin antagonist GR38032F(ondensetron) on the rate of apneas per hour of rapid-eye-movement (REM)sleep as compared to control. Each data point represents the mean±thestandard error for 9 rats (p=0.01 versus control).

FIG. 4 illustrates the effect of the serotonin antagonist GR38032F(ondensetron) on the percentage of total recording time spent in REMsleep as compared to control. Each data point represents the mean±thestandard error for 9 rats.

FIG. 5 shows the effects of the serotonin antagonist GR38032F(ondensetron) on the rate of normalized minute ventilation duringwakefulness, NREM and REM sleep as compared to control. Each data barrepresents the mean the standard error over 6 recording hours with allanimals (n=9) pooled (minute ventilation was significantly largerfollowing GR38032F administration in all behavioral states; p<0.03versus control).

FIG. 6 shows the effects of serotonin (0.79 mg/kg), GR38032F (0.1mg/kg)+serotonin (0.79 mg/kg), and GR38032F (0.1 mg/kg) on spontaneousapneas in NREM sleep. Each data bar represents the mean±the standarderror over 6 recording hours with all animals (n=10; p=0.97).

FIG. 7 illustrates the effects of serotonin (0.79 mg/kg), GR38032 (0.1mg/kg)+serotonin (0.79 mg/kg), and GR38032F (0.1 mg/kg) on spontaneousapneas during REM sleep. Each data bar represents the mean±the standarderror over 6 recording hours with all animals (n=10; p=0.01 forserotonin administration vs. control; p=0.05 for administration ofGR38032F+serotonin vs. serotonin alone; p=0.99 for administration ofGR38032F+serotonin vs. control; and p=0.51 for administration ofGR38032F alone).

DETAILED DESCRIPTION OF THE INVENTION

Previous studies on the effect of serotonin or serotonin analogs onrespiration in several anesthetized (see below) animal species havedemonstrated variable responses. For example, administration ofserotonin has been shown to cause an increase in the respiratory ratewith a decrease in tidal volume in rabbits, but an increase in the tidalvolume in dogs [Matsumoto, Arch. Int Pharmacodyn. Ther., 254:282-292(1981); Armstrong et al., J. Physiol. (Lond.), 365:104 P (1985); Bisgardet al., Resp. Physiol. 37:61-80 (1979); Zucker et al. Circ. Res. 47:509-515 (1980). In studies with cats, serotonin administration producedhyperventilation occasionally preceded by apnea [Black et al., Am. J.Physiol., 223:1097-1102 (1972); Jacobs et al., Circ. Res., 29:145-155(1971)], or immediate apnea followed by rapid shallow breathing[Szereda-Przestaszewska et al., Respir. Physiol., 101:231-237 (1995)].

Administration of 2-methyl-5-hydroxytryptamine, a selective5-hydroxytryptamine₃ receptor agonist, in cat studies caused apnea[Butler et al. Br. J. Pharmacol., 94:397-412 (1988)]. Intravenousadministration of serotonin, 2-methyl-5-hydroxytryptamine or a high doseof α-methyl-5-hydroxytryptamine, a 5-hydroxytryptamine-2 receptoragonist, produced transient apnea, the duration of which increased in adose-dependent fashion. This response was significantly antagonized byGR38032F(1,2,3,9-tetrahydro-9-methyl-3-[(2-methylimidazol-1-yl)methyl]carbazole-4-one,hydrochloride, dihydrate), a selective 5-hydroxytryptamine₃ receptorantagonist [Butler et al. Br. J. Pharmacol., 94:397-412 (1988); Hagan etal., Eur. J. Pharmacol., 138:303-305 (1987)] as well as by ketanserineand methysergide, 5-hydroxytryptamine₂ receptor antagonists [Yoshioka etal., J. Pharmacol. Exp. Ther., 260:917-924 (1992)]. In newborn rats,administration of serotonin precursor L-tryptophan, which activatedcentral serotonin biosynthesis, produced recurrent episodes ofobstructive apnea often followed by central apneas [Hilaire et al., J.Physiol., 466:367-382 (1993); Morin, Neurosci. Lett., 160:61-64 (1993)].

While the foregoing studies revealed significant information concerningthe involvement of serotonin in the development of apneas, as statedabove one significant problem with all of these studies is that theanimals were anesthetized, and thus any results obtained could not beattributed to a specific serotonin agonist or antagonist, i.e., aninteraction with the anesthesia or abnormal physiologic conditionsassociated with the anesthetic could not be ruled out.

Activity at serotonin receptors may also promote spontaneoussleep-related central apneas, which have been reported in rats,[Mendelson et al., Physiol. Behav., 43:229-234 (1988); Sato et al. Am.J. Physiol., 259:R282-R287 (1990); Monti et al., Pharmacol. Biochem.Behav., 125-131 (1995); Monti et al., Pharmacol. Biochem. Behav.,53:341-345 (1996); Thomas et al.,. J. Appl. Physiol., 78:215-218 (1992);Thomas et al., J. Appl. Physiol., 73:1530-1536 (1995); Carley et al.Sleep, 19:363-366 (1996); Carley et al., Physiol. Behav., 59:827-831(1996); Radulovacki et al., Sleep, 19:767-773 (1996); Christon et al.,J. Appl. Physiol., 80:2102-2107 (1996)]. In order to test thishypothesis, experiments were conducted to test the effects of aserotonin antagonist in freely moving animals in order to assess whetherblockade of serotonin receptors would inhibit expression of spontaneousapneas during NREM sleep and REM sleep. Experiments were also conductedto test the effects of serotonin and serotonin antagonists, singly andin combination, in freely moving animals in order to assess whetherincreased serotonergic activity at peripheral serotonin receptors maypromote sleep apneas.

The following examples illustrate the effects of administration ofserotonin receptor antagonists, and in particular GR38032F, to causesuppression of central apneas during non rapid eye movement (NREM) andespecially during rapid eye movement (REM) sleep. This effect wasassociated with increased respiratory drive but did not causecardiovascular changes at the dose tested.

The following examples also illustrate the effects of serotoninadministration to induce spontaneous apnea expression, which wascompletely antagonized via the administration of serotonin receptorantagonists, and in particular GR38032F.

The following examples further describe the pharmacological profilesbest suited for single agents or combinations of agents to successfullyprevent or ameliorate sleep-related breathing disorders, i.e.,

-   -   (a) a single agent or combination of agents having either        5-hydroxytryptamine₂ or 5-hydroxytryptamine₃ receptor subtype        antagonistic activity or both;    -   (b) a single agent or combination of agents having either        5-hydroxytryptamine₂ or 5-hydroxytryptamine₃ receptor subtype        antagonistic activity or both in conjunction with either        5-hydroxytryptamine, or 5-hydroxytryptamine₂ receptor subtype        agonistic activity or both; or    -   (c) a single agent or combination of agents having either        5-hydroxytryptamine₂ or 5-hydroxytryptamine₃ receptor subtype        antagonistic activity or both in conjunction with α₂ adrenergic        receptor subtype antagonistic activity.

Further aspects of the invention and embodiments will be apparent tothose skilled in the art. In order that the present invention is fullyunderstood, the following examples are provided by way ofexemplification only and not by way of limitation.

Example 1 describes the preparation of the animals for treatment witheither serotonin antagonists or agonists or both and subsequentphysiological recording and testing.

Example 2 describes the methods for the physiological recording oftreatment and control animals and results obtained from administrationof a serotonin antagonist.

Example 3 describes results obtained from the administration ofserotonin followed by the administration of a serotonin receptorantagonist.

Example 4 describes agents or compositions that posses a specificserotonin-related pharmacological activity that is used to effectivelysuppress or prevent sleep-related breathing disorders.

The following examples are illustrative of aspects of the presentinvention but are not to be construed as limiting.

EXAMPLE 1 Preparation of Animals for Physiological Testing and Recording

Adult, male Sprague-Dawley rats (Sasco-King, Wilmington, Mass.; usually8 per test group; 300 g) were maintained on a 12-hour light (08:00-20:00hour)/12-hour dark (20:00-08:00 hour) cycle for one week, housed inindividual cages and given ad libitum access to food and water.Following the one week of acclimatization, animals were subjected to thefollowing surgical procedures.

Acclimatized animals were anesthetized for the implantation of corticalelectrodes for electroencephalogram (EEG) recording and neck muscleelectrodes for electromyogram (EMG) recording using a mixture ofketamine (Vedco, Inc., St. Joseph, Mo.; 100 mg/ml) and acetylpromazine(Vedco, Inc., St. Joseph, Mo.; 10 mg/ml; 4:1, volume/volume) at a volumeof 1 ml/kg body weight. The surface of the skull was exposed surgicallyand cleaned with a 20% solution of hydrogen peroxide followed by asolution of 95% isopropyl alcohol. Next, a dental preparation of sodiumfluoride (Flura-GEL®, Saslow Dental, Mt. Prospect, Ill.) was applied toharden the skull above the parietal cortex and allowed to remain inplace for 5 minutes. The fluoride mixture was then removed from theskull above the parietal cortex. The EEG electrodes consisting of fourstainless steel machine screws, having leads attached thereto, werethreaded into the skull to rest on the dura over the parietal cortex. Athin layer of Justi® resin cement (Saslow Dental, Mt. Prospect, Ill.)was applied to cover the screw heads (of screws implanted in the skull)and surrounding skull to further promote the adhesion of the implant.EMG electrodes consisting of two ball-shaped wires were inserted intothe bilateral neck musculature. All leads (i.e., EEG and EMG leads) weresoldered to a miniature connector (39F1401, Newark Electronics,Schaumburg, Ill.). Lastly, the entire assembly was fixed to the skullwith dental cement.

After surgery, all animals were allowed to recover for one week beforebeing subjected to another surgery that involved implantation of aradiotelemetry transmitter (TA11-PXT, Data Sciences International, St.Paul, Minn.) for monitoring blood pressure (BP) and heart period (HP),estimated as pulse interval. After the animals were anesthetized (asdescribed above), the hair from the subxiphoid space to the pelvis wasremoved. The entire area was scrubbed with iodine and rinsed withalcohol and saline. A 4-6 cm midline abdominal incision was made toallow good visualization of the area from the bifurcation of the aortato the renal arteries. A retractor was used to expose the contents ofthe abdomen and the intestine was held back using saline moistened gauzesponges. The aorta was dissected from the surrounding fat and connectivetissues using sterile cotton applicators. A 3-0 silk suture was placedbeneath the aorta and traction was applied to the suture to restrict theblood flow. Then the implant (TA11-PXT) was held by forceps while theaorta was punctured just cranial to the bifurcation using a 21-gaugeneedle bent at the beveled end. The tip of the catheter was insertedunder the needle using the needle as a guide until the thin-walled BPsensor section was within the vessel. Finally, one drop of tissueadhesive (Vetbond®, 3M, Minneapolis, Minn.) was applied to the puncturesite and covered with a small square of cellulose fiber (approximately 5mm²) so as to seal the puncture after catheter insertion. The radioimplant was attached to the abdominal wall by 3-0 silk suture, and theincision was closed in layers. After the second surgery, animals wereagain allowed a one week recovery period prior to administration of theserotonin receptor antagonist and subsequent physiological recording.

EXAMPLE 2 Physiological Recording and Suppression of Apneas

Physiological parameters (see below) from each animal were recorded on 2occasions in random order, with recordings for an individual animalseparated for at least 3 days. Fifteen minutes prior to each recordingeach animal received a systemic injection (1 ml/kg intraperitoneal bolusinjection) of either saline (control) or 1 mg/kg of ondensetron(GR38032F;1,2,3,9-tetrahydro-9-methyl-3-[(2-methylimidazol-1-yl)methyl]carbazole-4-one,hydrochloride, dihydrate; Glaxo Wellcome, Inc., Research Triangle Park,N.C.). Polygraphic recordings were made from hours 10:00-16:00.

Respiration was recorded by placing each animal, unrestrained, inside asingle chamber plethysmograph (PLYUN1R/U; Buxco Electronics, Sharon,Conn.; dimension 6 in.×10 in.×6 in.) ventilated with a bias flow offresh room air at a rate of 2 L/min. A cable plugged onto the animal'sconnector and passed through a sealed port was used to carry thebioelectrical activity from the head implant. Respiration, bloodpressure, EEG activity, and EMG activity were displayed on a videomonitor and simultaneously digitized 100 times per second and stored oncomputer disk (Experimenter's Workbench; Datawave Technologies,Longmont, Colo.).

Sleep and waking states were assessed using the biparietal EEG andnuchal EMG signals on 10-second epochs as described by Bennington et al[Sleep, 17:28-36 (1994)]. This software discriminated wakefulness (W) asa high frequency low amplitude EEG with a concomitant high EMG tone,NREM sleep by increased spindle and theta activity together withdecreased EMG tone, and REM sleep by a low ratio of a delta to thetaactivity and an absence of EMG tone. Sleep efficiency was measured asthe percentage of total recorded epochs staged as NREM or REM sleep.

An accepted physiological animal model [rat; Monti, et al., Pharamcol.Biochem. Behav., 51:125-131 (1995)] of spontaneous sleep apnea was usedto assess the effects of GR38032F. More specifically, sleep apneas,defined as cessation of respiratory effort for at least 2.5 seconds,were scored for each recording session and were associated with thestage of sleep in which they occurred: NREM or REM sleep. The durationrequirement of 2.5 seconds represented at least 2 “missed” breaths,which is therefore analogous to a 10 second apnea duration requirementin humans, which also reflects 2-3 missed breaths. The events detectedrepresent central apneas because decreased ventilation associated withobstructed or occluded airways would generate an increasedplethysmographic signal, rather than a pause. An apnea index (AI),defined as apneas per hour in a stage were separately determined forNREM and REM sleep. The effects of sleep stage (NREM vs. REM) andinjection (control vs. GR30832F) were tested using ANOVA with repeatedmeasures. Multiple comparisons were controlled using Fisher's protectedleast significant difference (PLSD). In addition, the timing and volumeof each breath were scored by automatic analysis (Experimenters'Workbench; Datawave Technologies, Longmont, Conn.). For each animal themean respiratory rate (RR) and minute ventilation (MV) was computed forW throughout the 6 hour control recording and used as a baseline tonormalize respiration during sleep and during GR38032F administration inthat animal. One way ANOVA was also performed by non-parametric(Kruskal-Wallis) analysis. Conclusions using parametric andnon-parametric ANOVA were identical in all cases.

Similar software (Experimenters' Workbench; Datawave Technologies,Longmont, Colo.) was employed to analyze the blood pressure waveform;for each beat of each recording, systolic (SBP) and diastolic (DBP)blood pressures and pulse interval were measured. The pulse intervalprovided a beat by beat estimate of HP. Mean BP (MBP) was estimatedaccording to the weighted average of SBP and DBP for each beat:MBP=DBP+(SBP-DBP)/3. The parameters for each beat were also classifiedaccording to the sleep/wake state and recording hour during which theyoccurred.

Results of the administration of the serotonin antagonist GR38032F onthe rate of apneas per hour of NREM sleep during the 6 hours ofpolygraphic recording (see FIG. 1) demonstrated no significant effect oftreatment or time over 6 hours (two-way ANOVA). However, there was asignificant suppression of apneas during the first 2 hours of recordingas determined by paired t-tests (p<0.01 for each). This respiratoryeffect was associated with a significant suppression of NREM sleep bythe GR38032F during the first 2 hours as demonstrated in FIG. 2. Thepercentage of NREM sleep in 6 hour recordings was lower in GR38032Fadministered rats than in controls, but the decrease reached statisticalsignificance only during the first 2 hours of the recordings (p<0.001).

Results further indicated a significant suppressant effect of GR38032Fon REM sleep apneas throughout the 6 hour recording period (p=0.01 fordrug effect on 2-way ANOVA; see FIG. 3). This effect was particularlymanifest during the first 4 hours of recordings, during which no animalexhibited a single spontaneous apnea in REM sleep. This effect was not asimple reflection of REM suppression during the first 4 hours.

Results set forth in FIG. 4 show that GR38032F did not significantlyaffect REM sleep. Although REM sleep in drug treated animals was lowerthan in corresponding controls it did not reach statistical significanceoverall or during any single recording hour.

Results of the administration of GR38032F on the normalized minuteventilation during W (wake), NREM (non-rapid eye movement) sleep, andREM (rapid eye movement) sleep (see FIG. 5) indicate a significantstimulation of ventilation during all behavioral states (p=0.03 foreach). Finally, results indicate that GR38032F had no effect on anycardiovascular variable (MBP and HP during W, NREM, and REM sleep)measured p>0.1 for each variable; see Table 1).

TABLE 1 Effects of GR38032F on Cardiovascular Variables Mean BP (mm Hg)HP (msec) W NREM REM W NREM REM Control 111 ± 18 110 ± 18 108 ± 18 174 ±5 181 ± 5 185 ± 6 GR38032F 113 ± 18 112 ± 17 110 ± 17 183 ± 3 189 ± 3190 ± 3 All values are mean ± SE.

Overall these results indicate that the manipulation of serotonergicsystems can exert a potent influence on the generation of central apneasin both REM and NREM sleep. Specifically the present findings indicatethat systemic administration of a 5-hydroxytryptamine₃ receptorantagonist suppresses spontaneous apnea expression; completelyabolishing REM-related apnea for at least 4 hours after intraperitonealinjection. This apnea suppression was associated with a generalizedrespiratory stimulation that was observed as increased minuteventilation during both waking and sleep. These significant respiratoryeffects were observed at a dose which caused no change in heart rate orblood pressure, even during the first 2 hours, when respiration wasmaximal.

Those of skill in the art will recognize that exemplary serotoninreceptor antagonists in its free base form or as a quaternary ammoniumsalt include, but are not limited to (a) ketanserin, cinanserin,LY-53,857, metergoline, LY-278,584, methiothepin, p-NPPL, NAN-190,piperazine, SB-206553, SDZ-205,557, 3-tropanyl-indole-3-carboxylate,3-tropanyl-indole-3-carboxylate methiodide, methysergide (ResearchBiochemicals, Inc., Natick, Mass.); (b) risperidone (JanssenPharmaceutica, Titusville, N.J.); (c) cyproheptadine, clozapine,mianserin, ritanserin (Sigma Chemical Co., St. Louis, Mo.); (d)ondensetron, granisetron (SmithKline Beecham, King of Prussia, Pa.),zatosetron, tropisetron, dolasetron, and hydrodolasetron; (e) loxapine,olanzapine, chlorpromazine, haloperidol, r (+) ondensetron, cisapride,norcisapride, (+) cisapride, (−) cisapride, (+) norcisapride, (−)norcisapride, desmethylolanzapine, 2-hydroxymethylolanzapine,1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime,(f) mescaline, oxetorone, homochlorcyclizine, and perlapine and otherserotonin receptor antagonists and any of their quaternary form orpharmaceutically acceptable salts may be used to prevent or amelioratesleep-related breathing disorders. Further, those of skill in the artwill also recognize that the results discussed above may be easilycorrelated to other mammals, especially primates (e.g., humans).

EXAMPLE 3 Induction and Suppression of Sleep Apneas

Administration of serotonin or serotonin analogs produced variablerespiratory responses in anesthetized animals of several species (seeabove, DETAILED DESCRIPTION OF THE INVENTION). As shown above in Example2, intraperitoneal administration of 1 mg/kg GR38032F, a selective5-hydroxytryptamine₃ receptor antagonist, suppressed spontaneous centralapneas. This effect was especially prominent in REM sleep, during whichapneas were completely abolished for at least 4 hours followinginjection. The apnea suppressant effect of GR38032F was paralleled byincreased respiratory drive, but BP and heart rate changes were absentat the dose tested.

Suppression of spontaneous apneas during natural sleep by GR38032F (seeExample 2) is consistent with prior studies in anesthetized rats,wherein 5-hydroxytryptamine and 2-methyl-5-hydroxytryptamine, aselective 5-HT₃ receptor agonist, provoked central apneas that wereantagonized by GR38032F. Since 5-hydroxytryptamine does not penetratethe blood-brain barrier (BBB), these results (from the prior studies)indicate that stimulation of peripheral 5-hydroxytryptamine receptors,and more particularly 5-hydroxytryptamine₃ receptors seemed to haveprovoked the occurrence of central apneas. In view of that study,performed in anesthetized animals, as well as our study (described inExample 2 above) in freely moving rats with respect to administration ofGR38032F, we studied the ability of increased serotonergic activity atperipheral 5-hydroxytryptamine receptors, and more specifically,5-hydroxytryptamine₃ receptors to promote spontaneous sleep-relatedcentral apneas and whether any induction of apneas would be susceptibleto antagonism by administration of 5-hydroxytryptamine receptorantagonists.

Ten adult male Sprague-Dawley rats (Sasco-King, Wilmington, Mass.; 300g) were maintained on a 12-h light (08:00-20:00 hour)/12-hour dark(20:00-08:00) cycle for one week, housed in individual cages, and givenad libitum access to food and water. Following the one week ofacclimatization, animals were prepared for physiological testing via thesurgical procedures (i.e., implantation of cortical electrodes for EEGrecording and neck muscle electrodes for EMG recording, implantation ofa radiotelemetry transmitter for BP and HP monitoring) as set forthabove in Example 1. After completion of the surgical procedures, animalswere allowed a one week recovery period prior to use in the presentstudy.

Each animal was recorded on four occasions, with recordings for anindividual animal separated by at least three days. Fifteen minutesprior to each recording, each animal received (via intraperitonealinjection), in random order, one of the following:

(a) saline solution (control); (b) 0.79 mg/kg serotonin; (c) 0.1 mg/kgGR38032F plus 0.79 mg/kg serotonin; or (d) 0.1 mg/kg GR38032F. For theGR38032F+serotonin test group, 0.1 mg/kg GR38032F was administered attime 09:30 followed by 0.79 mg/kg serotonin at time 09:45. Polygraphicrecordings were made from 10:00-16:00.

Respiration BP, EEG, and EMG data were determined and recorded via theexperimental procedure as specifically set forth above in Example 2. Asin Example 2, sleep apneas, defined as cessation of respiratory effortfor at least 2.5 s, were scored for each recording session and wereassociated with the stage in which they occurred: NREM or REM sleep. Theduration requirement of 2.5 s represents at least two “missed” breaths,which is analogous to a 10-s apnea duration requirement in humans.

The effects of sleep stage (NREM vs REM) and injection (control vs.administration of either serotonin alone, GR38032F+serotonin, orGR38032F alone) on apnea indexes, respiratory pattern, BP, and HP weretested using analysis of variance (ANOVA) with repeated measures.Multiple comparisons were controlled using Fisher's protectedleast-significance difference (PLSD). One-way ANOVA was also performedby nonparametric (Kruskal-Wallis) analysis. Conclusions using parametricand nonparametric ANOVA were identical in all cases.

Results of the administration of either serotonin alone (0.79 mg/kg),GR38032F (0.1 mg/kg)+serotonin (0.79 mg/kg), or GR38032F alone (0.1mg/kg) on the ability to promote spontaneous apneas in NREM sleep duringa 6 hour polygraphic recording is set forth in FIG. 6. Specifically,during NREM sleep, the spontaneous apnea index was not affected by anydrug treatment.

As illustrated in FIG. 7, spontaneous apnea expression during REM sleepsignificantly increased following administration of serotonin ascompared to control recording (>250% increase). Results also indicatethat such an increase was abolished via prior administration ofGR38032F. At the low dose tested (0.1 mg/kg) administration of GR38032Falone had no effect on REM sleep spontaneous apneas.

As set forth in Table 2 (percentages of waking, NREM, and REM sleepduring 6 hours of polygraphic recording following drug administration),intraperitoneal administration of serotonin alone, GR38032F+serotonin,or GR38032F alone had no effect on sleep architecture. Finally, notreatment group tested had a significant effect on RR, VE, mean BP, HP,or PS apnea index (data not shown).

TABLE 2 Effects of 5-HT and GR38032F on Sleep/Wake Architecture %Wakefulness % NREM % REM Control (saline solution) 33.7 ± 2.5* 58.0 ±1.9 6.9 ± 1.1 5-HT (0.79 mg/kg) 30.2 ± 3.2  59.9 ± 3.3 6.5 ± 1.1 5-HT +GR38032F 36.7 ± 8.7  56.0 ± 7.6 5.3 ± 1.4 GR38032F (0.1 mg/kg) 28.8 ±6.4  63.4 ± 5.7 7.3 ± 2.3 p (1-way ANOVA) 0.43 0.71 0.60 *All valuesreflect means ± SE for percent recording time.

Overall these results indicate that manipulation of peripheral serotoninreceptors exerts a potent influence on the generation of central apneasduring REM sleep. Specifically, the present results show that systemicadministration of serotonin increases spontaneous apnea expression insleep. Although the dose of serotonin employed had no effect on sleep,cardiovascular variables, RR, or VE, the REM-related spontaneous apneaindex increased >250%. Further, it is important to note that themechanisms of apnea genesis are at least partially sleep-state specific,as NREM apneas were unaffected.

These findings demonstrate that exogenous administration of5-hydroxytryptamine₃ agonists and antagonists at various doses produceschanges in apnea expression that are specific to REM sleep. Suchfindings indicate that there is a physiologic role for endogenousserotonergic activity in modulating the expression of apnea, especiallyduring REM sleep. Moreover, because serotonin does not cross theblood-brain barrier, the finding that serotonin exerts a converse effectto GR38032F indicates that the relevant receptors are located in theperipheral nervous system. Further, the present data suggest that theaction of supraphysiologic levels of serotonin on apneas is receptormediated in that pretreatment with a low dose (0.1 mg/kg) of GR38032F,which had no independent effect on any measured parameter, includingapneas, fully blocked the effects of exogenous serotonin on apneaexpression.

In view of the foregoing data, the likely peripheral site of action forthe observed apnea-promoting effects of serotonin administration isthought to be the nodose ganglia of the vagus nerve. More specifically,several studies have concluded that the apnea component of theBezold-Jarisch reflex results from the action of serotonin at the nodoseganglia in cats [Jacobs et al, Circ. Res., 29:145-155 (1971), Sampson etal., Life Sci., 15:2157-2165 (1975), Sutton, Pfllugers Arch.,389:181-187 (1981)] and rats [Yoshioka et al., J. Pharmacol. Exp. Ther.,260:917-924 (1992) and McQueen et al., J. Physiol, 5073:843-855 (1998)].Intravenous administration of serotonin or 5-hydroxytryptamine₃ receptoragonists also stimulates pulmonary vagal receptors [McQueen et al., J.Physiol., 5073:843-855 (1998)], which may contribute significantly tothe apneic response.

Although species differences may be present [Black et al., Am. J.Physiol., 223:1097-1102 (1972)], several studies in rat demonstratethat, in addition to its impact on vagal signaling, serotonin alsoelicits increased firing from carotid body chemoreceptors [McQueen etal., J. Physiol., 5073:843-855 (1998); Sapru et al, Res. Comm. Chem.Pathol. Pharmacol., 16:245-250 (1977); Yoshioka, J. Pharmacol. Exp.Ther., 250:637-641 (1989) and Yoshioka et al., Res. Comm. Chem. Pathol.Pharmacol., 74:39-45 (1991)] and increased VE [McQueen et al., J.Physiol., 5073:843-855 (1998); Sapru et al., Res. Comm. Chem. Pathol.Pharmacol., 16:245-250 (1977)]. Although chemoreceptor-mediated effectson apnea cannot be ruled out, the data of McQueen et al., J. Physiol.,5073:843-855 (1998) strongly indicate that intravenous serotonin elicitsapnea via a vagal pathway, while the chemoreceptor activation opposesapnea genesis in the anesthetized rat.

The serotonin-induced Bezold-Jarisch reflex in anesthetized animalsincludes apnea and bradycardia. At the dose employed, serotonin did notelicit changes in either heart rate or mean BP over the 6 hour recordingperiod. Beat-to-beat heart rate and BP variability, assessed ascoefficients of variation, were also unaffected by serotonin at the dosetested. The observed dissociation of cardiovascular and respiratoryresponses to serotonin indicates that changes in apnea expression werenot baroreceptor mediated.

Although the Bezold-Jarisch reflex in anesthetized animals andserotonin-induced apneas in REM sleep are not the same phenomenon, theymay be related by similar mechanisms. When serotonin receptors arestrongly manipulated by exogenous means, i.e., either with serotonergicagonists or antagonists, the expression of spontaneous apneas in REMsleep can be amplified or suppressed. However, our observation that 1mg/kg GR38032F significantly suppressed REM apneas does not preclude arole for 5-hydroxytryptamine₂ or other 5-hydroxytryptamine receptorsubtypes in the peripheral regulation of the apnea expression, andinfact the invention also contemplates the use of 5-hydroxytryptamine₂and 5-hydroxytryptamine₃, alone or in combination as well as serotoninantagonists that exhibit both type 2 and type 3 receptor antagonism (seeExample 4).

It has been well established [Mendelson et al., Physiol. Behav.,43:229-234 (1988); Sato et al., Am. J. Physiol., 259:R282-287 (1990);Monti et al., Pharmacol. Biochem. Behav., 51:125-131 (1995); Monti etal., Pharmacol Biochem. Behav., 53:341-345 (1996); Thomas et al., J.Appl. Physiol., 73:1530-1536 (1992) and Thomas et al, J. Appl. Physiol.,78:215-218 (1995)] that apnea frequency in rats increases from deepslow-wave sleep to light NREM sleep to REM sleep, as is the case in man.The high incidence of apnea expression during REM sleep may be relatedto respiratory changes that take place during this sleep state.Typically, during REM sleep, breathing becomes shallow and irregular[Orem et al., Respir. Physiol., 30:265-289 (1977); Phillipson, Annu.Rev. Physiol., 40:133-156 (1978); Sieck et al., Exp. Neurol., 67:79-102(1980) and Sullivan, In: Orems et al, eds., “Physiology in sleep,”Academic Press, New York, N.Y., pp. 213-272 (1980)] and VE is at itslowest point [Hudgel et al, J. Appl. Physiol., 56:133-137 (1984)]. Thisbackground of low respiratory output coupled with strong phasic changesin autonomic activity [Mancia et al., In; Orem et al., eds., “Physiologyin sleep,” Academic Press, New York, N.Y., pp. 1-55 (1980)] would renderrespiratory homeostasis during REM sleep more vulnerable to interruptionby apnea. Thus it is possible that the role of serotonin activity in theperipheral nervous system in REM apnea genesis may arise from aserotonergic modulation of either tonic or phasic activity ofrespiratory afferent activity, especially in the vagus nerves.Therefore, the brainstem respiratory integrating areas may be renderedmore vulnerable to fluctuating afferent inputs during REM sleep.

Overall, the results presented herein indicate that the exacerbation ofspontaneous apnea during REM sleep produced by peripherally administeredserotonin is receptor mediated. Such findings also indicate aphysiologic role for endogenous serotonin in the peripheral nervoussystem in modulating sleep apnea expression under baseline conditions.

EXAMPLE 4 Suppression or Prevention of Sleep Apneas

As indicated by the data presented herein (see Examples 2 and 3)serotonin plays an important and integral role in apnea genesis, whichis both highly site and receptor subtype specific. More specifically,the efficacy of a serotonin receptor antagonist to suppress apnea isbased on its activity in the peripheral nervous system, with the nodoseganglia of the vagus nerves appearing to be a crucial target site.5-hydroxytryptamine₂ and 5-hydroxytryptamine₃ receptors at this site areclearly implicated in serotonin-induced apnea in anesthetized animals[Yoshioka et al, J. Pharmacol. Exp. Therp., 260:917-924 (1992)]. Inconjunction with these previous findings, the data presented herein(that administration of serotonin strictly to the peripheral nervoussystem exacerbates sleep-related apnea) indicates the importance ofnodose ganglion serotonin receptors of both types in sleep apneapathogenesis. Moreover, the serotonin-induced increase in apneaexpression was completely blocked by a low dose of GR38032F, a5-hydroxytryptamine₃ antagonist. Such a result indicates that thepreviously demonstrated suppression of apnea by GR38032F (see Example 2)most probably resulted from activity in the peripheral nervous system.

Therefore, in view of the foregoing, sleep related breathing disorders(sleep apnea syndrome, apnea of infancy, Cheyne-Stokes respiration,sleep-related hypoventilation syndromes) may be effectively prevented orsuppressed via systemic administration of pharmacological agentsexhibiting either serotonin type 2 or type 3 receptor antagonism, aloneor in combination as well as agents that exhibit both serotonin type 2and type 3 receptor antagonism.

Effective treatments for the prevention or suppression of sleep-relatedbreathing disorders include systemic administration of a5-hydroxytryptamine₂ or 5-hydroxytryptamine₃ receptor antagonist eitheralone or in combination. In a preferred embodiment the serotoninreceptor antagonist has activity only in the peripheral nervous systemand/or does not cross the blood-brain barrier. In a more preferredembodiment the serotonin receptor antagonist displays both5-hydroxytryptamine₂ and 5-hydroxytryptamine₃ receptor subtypeantagonism.

Current pharmacological treatments for sleep-related breathing disordersalso involve apnea suppression via serotonin agonist effects within thecentral nervous system, and more specifically the brainstem. Indeed, itwas in view of their potential to stimulate respiration and upper airwaymotor outputs that serotonin enhancing drugs were originally tested aspharmacological treatments for sleep apnea syndrome. One early reportsuggested that L-tryptophan, a serotonin precursor, may have abeneficial effect on sleep apnea syndrome [Schmidt, Bull. Eur. Physiol.Respir., 19:625-629 (1982)]. More recently fluoxetine [Hanzel et al.,Chest., 100:416-421 (1991)] and paroxetine [Kraiczi et al., Sleep,22:61-67 (1999)], both selective serotonin reuptake inhibitors (SSRIs),were demonstrated to benefit some but not all patients with sleep apneasyndrome. In addition, combinations of serotonin precursors and reuptakeinhibitors reduced sleep disordered respiration in English bulldog modelof sleep apnea syndrome [Veasey et al., Sleep Res., A529; 1997 andVeasey et al., Am. J. Resp. Crit. Care Med., 157:A655 (1997)]. However,despite ongoing investigations these encouraging early results withserotonin enhancing drugs have not been reproduced.

The foregoing efforts with serotonin-enhancing drugs indicate that thepotential utility of serotonin precursors or SSRIs in apnea treatmentresides strictly in their central nervous system effects. Therefore, itis precisely because the serotonin enhancing effects of SSRIs in theperipheral nervous have been left unchecked that these compounds havenot demonstrated reproducible effects in apnea treatment. In factbuspirone, a specific 5-hydroxytryptamine_(1A) agonist, which stimulatesrespiration [Mendelson et al., Am. Rev. Respir. Dis., 141:1527-1530(1990)], has been shown to reduce apnea index in 4 of 5 patients withsleep apnea syndrome [Mendelson et al., J. Clin. Psychopharmacol.,11:71-72 (1991)] and to eliminate post-surgical apneustic breathing inone child [Wilken et al., J. Pediatr., 130:89-94 (1997). Althoughbuspirone acts systemically, 5-hydroxytryptamine, receptors in theperipheral nervous system have not been shown to play a role in apneagenesis. The modest apnea suppression induced by buspirone is a centralnervous system effect that goes unopposed by serotonergic effects in theperipheral nervous system.

The rationale for using SSRIs such as fluoxetine or paroxetine to treatsleep apnea syndrome rests in part on their ability to stimulate upperairway motor outputs. Applications of serotonin to the floor of thefourth ventricle [Rose et al., Resp. Physiol., 101:59-69 (1995)] or intothe hypoglossal motor nucleus [Kubin et al., Neurosci. Lett.,139:243-248 (1992)] produce upper airway motor activation in cats;effects which appear to be mediated predominantly by5-hydroxytryptamine₂ receptors. Conversely, systemic administration of5-hydroxytryptamine₂ receptor antagonists to English bulldogs reduceselectrical activation of upper airway muscles, diminishes upper airwaycross-sectional area and promotes obstructive apnea [Veasey et al., Am.J. Crit. Care Med., 153:776-786 (1996)]. These observations provide alikely explanation for the improvements in sleep-disordered breathingobserved in some patients following SSRI treatment.

In conjunction with the data presented herein (Examples 2 and 3) and theforegoing observations, sleep related breathing disorders (sleep apneasyndrome, apnea of infancy, Cheyne-Stokes respiration, sleep-relatedhypoventilation syndromes) may be effectively prevented or suppressedvia systemic administration of

-   -   (a) an agent or combinations of agents exhibiting either        serotonin type 2 or type 3 receptor antagonism (either alone or        in combination with one another) and/or in combination with        either a 5-hydroxytryptamine, or 5-hydroxytryptamine₂ receptor        agonist;    -   (b) an agent or combination of agents or agents that exhibit        both serotonin type 2 and type 3 receptor antagonism in        combination with either a 5-hydroxytryptamine, or        5-hydroxytryptamine₂ receptor agonist; or    -   (c) agents that exhibit both the proper antagonistic and        agonistic pharmacological profile (i.e., an agent that is both        an agonist and antagonist at the receptor subtypes set forth        above).        Preferred embodiments include the following:    -   (a) an agent or combination of agents wherein the serotonin        agonist exhibits only central serotonergic actions;    -   (b) an agent or combination of agents wherein the serotonin        agonist exhibits only central 5-hydroxytryptamine₂ actions;    -   (c) an agent or combination of agents s wherein the serotonin        antagonist exhibits only peripheral actions while the serotonin        agonist exhibits only central serotonergic actions;    -   (d) an agent or combination of agents that have the ability to        induce central nervous system serotonin release and that possess        the antagonistic profile discussed above (i.e. both a        5-hydroxytryptamine₂ and 5-hydroxytryptamine₃ receptor        antagonist); or    -   (e) an agent or combination of agents that have the ability to        induce central nervous system serotonin release and possess only        peripheral antagonistic effects;

Those of skill in the art will recognize that many serotonin receptoragonists such as, but not limited to 8-OH-DPAT(8-hydroxy-2-(di-n-propylamino)tetralin, sumatriptan, L694247(2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine),buspirone, alnitidan, zalospirone, ipsapirone, gepirone, zolmitriptan,risatriptan, 311C90, α-Me-5-HT, BW723C86(1-[5(2-thienylmethoxy)-1H-3-indolyl[propan-2-amine hydrochloride), MCPP(m-chlorophenylpiperazine), as well as others may be used in conjunctionwith serotonin receptor antagonists to prevent or amelioratesleep-related breathing disorders.

Pharmacological mechanisms of action other than serotonin precursors orSSRIs may also be exploited to enhance central nervous system serotoninactivity. Indeed, at least one mechanism allows augmented serotoninrelease to be selectively targeted at the central nervous system.Specifically, antagonism of presynaptic α₂ adrenergic receptors locatedon brainstem serotonergic neurons (heteroreceptors) enhances serotoninrelease. Selective 5-hydroxytryptamine₂ and 5-hydroxytryptamine₃receptor antagonists have been shown to block presynapticα₂-adrenoreceptors as well as postsynaptic 5-hydroxytryptamine₂ and5-hydroxytryptamine₃ receptors [deBoer, J. Clin. Psychiatr., 57(4):19-25(19960; Devane, J. Clin. Psychiatry., 59(20):85-93 (1998); andPuzantian, Am. J. Health-Syst. Pharm., 55:44-49 (1998)]. Because theaffinity of such agents for central α₂ receptors is 10 times higher thanfor peripheral α₂ receptors [Puzantian, Am. J. Health-Syst. Pharm.,55:44-49 (1998)], central serotonin release is increased with minimaladrenergic side effects such as hypertension. Thus because thesepharmacological agents are high affinity antagonists at5-hydroxytryptamine_(2A), 5-hydroxytryptamine_(2C) and5-hydroxytryptamine₃ receptors, the net effect is increasedpost-synaptic 5-hydroxytryptamine, activity within the brain and reduced5-hydroxytryptamine₂ and 5-hydroxytryptamine₃ post-synaptic activity inthe central and peripheral nervous systems. Each of thesepharmacological effects serve to stimulate respiration and suppressapnea.

In view of the foregoing observations, sleep related breathing disorders(sleep apnea syndrome, apnea of infancy, Cheyne-Stokes respiration,sleep-related hypoventilation syndromes) may also be effectivelysuppressed or prevented via systemic administration of pharmacologicalagents of combinations of agents having α₂ adrenergic antagonistactivity with either serotonin type 2 or type 3 receptor antagonistactivity (either alone or in combination with one another). Preferredembodiments include:

-   -   (a) an agent or combination of agents wherein the α₂ adrenergic        antagonist effects are exerted centrally;    -   (b) an agent or combination of agents wherein the serotonin        antagonist effects are exerted peripherally;    -   (c) an agent or combination of agents wherein the α₂ adrenergic        antagonist effects are exerted centrally and the serotonin        antagonist effects are exerted peripherally;    -   (d) the agent or combination of agents of embodiments a-c        wherein the α₂ adrenergic antagonist effect is exerted        presynaptically;    -   (e) the agent or combination of agents of embodiments a-d        wherein the α₂ adrenergic antagonist effects are exerted        selectively at presynaptic heteroreceptors on serotonergic        neurons; or    -   (f) the agent or combination of agents of embodiments a-d in        which the α₂ adrenergic antagonist effect is exerted by an agent        or combination of agents possessing the following        pharmacological profile: α₂ adrenergic antagonist activity with        both serotonin type 2 or type 3 receptor antagonist activity.

Those of skill in the art will recognize that many α₂ adrenergicreceptor antagonists such as, but not limited to phenoxybenzamine,phentolamine, tolazoline, terazosine, doxazosin, trimazosin, yohimbine,indoramin, ARC239, prazosin as well as others may be used in conjunctionwith serotonin receptor antagonists to prevent or amelioratesleep-related breathing disorders

An individual diagnosed with a sleep-related breathing disorder isadministered either a composition or agent having any of the foregoingpharmacological profiles in an amount effective to prevent or suppresssuch disorders. The specific dose may be calculated according to suchfactors as body weight or body surface. Further refinement of thecalculations necessary to determine the appropriate dosage for treatmentof sleep-related breathing disorders is routinely made by those ofordinary skill in the art without undue experimentation. Appropriatedosages may be ascertained through use of established assays fordetermining dosages. Routes of administration for the foregoing methodsmay be by any systemic means including oral, intraperitoneal,subcutaneous, intravenous, intramuscular, transdermal, or by otherroutes of administration. Osmotic mini-pumps and timed-released pelletsor other depot forms of administration may also be used.

Finally, those of skill in the art will recognize that with respect tothe compounds discussed above, such compounds may contain a center ofchirality. Thus such agents may exist as different enantiomers ofenantiomeric mixtures. Use of any one enantiomer alone or containedwithin an enantiomeric mixture with one or more stereoisomers iscontemplated by the present invention.

Although the present invention has been described in terms of preferredembodiments, it is intended that the present invention encompass allmodifications and variations that occur to those skilled in the art uponconsideration of the disclosure herein, and in particular thoseembodiments that are within the broadest proper interpretation of theclaims and their requirements. All literature cited herein isincorporated by reference.

1. A method of ameliorating a sleep-related breathing disordercomprising administering to a patient in need thereof an effectiveamount of at least one serotonin receptor antagonist, in free base orquaternized form, selected from the group consisting of hydrodolasetron,mescaline, homochlorcyclizine, perlapine, loxapine, chlorpromazine,haloperidol, desmethylolanzapine, 2-hydroxymethylolanzapine, and1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime.2. The method of claim 1 wherein the sleep-related breathing disorder isselected from the group consisting of obstructive sleep apnea syndrome,apnea of prematurity, congenital central hypoventilation syndrome,obesity hypoventilation syndrome, central sleep apnea syndrome,Cheyne-Stokes respiration, and snoring.
 3. A method of ameliorating asleep-related breathing disorder comprising administering to a patientin need thereof an effective amount of at least one serotonin receptorantagonist, in quaternized form, selected from the group consisting ofketanserin, risperidone, cyproheptadine, clozapine, methysergide,mianserin, ritanserin, cinanserin, LY-53,857, metergoline, LY-278,584,methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557,3-tropanyl-indole-3-carboxylate, and 3-tropanyl-indole-3-carboxylatemethiodide.
 4. The method of claim 3 wherein the sleep-related breathingdisorder is selected from the group consisting of obstructive sleepapnea syndrome, apnea of prematurity, congenital central hypoventilationsyndrome, obesity hypoventilation syndrome, central sleep apneasyndrome, Cheyne-Stokes respiration, and snoring.
 5. A method ofameliorating a sleep-related breathing disorder comprising administeringto a patient in need thereof an effective amount of (a) at least one ofa serotonin receptor antagonist (i) in free base or quaternized formselected from the group consisting of hydrodolasetron, mescaline,homochlorcyclizine, perlapine, loxapine, chlorpromazine, haloperidol,desmethylolanzapine, 2-hydroxymethylolanzapine, and1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime;(ii) in quaternized form selected from the group consisting ofondensetron, ketanserin, risperidone, cyproheptadine, clozapine,methysergide, mianserin, ritanserin, cinanserin, LY-53,857, metergoline,LY-278,584, methiothepin, p-NPPL, NAN-190, piperazine, SB-206553,SDZ-205,557, 3-tropanyl-indole-3-carboxylate, and3-tropanyl-indole-3-carboxylate methiodide; and (iii) and mixturesthereof; and (b) a serotonin receptor agonist.
 6. The method of claim 5wherein the serotonin receptor antagonist in the quaternized form ismethylated, ethylated, or benzylated.
 7. The method of claim 5 whereinthe serotonin receptor agonist is selected from the group consisting of8-OH-DPAT, sumatriptan, L694247, buspirone, alnitidan, zalospirone,ipsapirone, gepirone, zolmitriptan, risatriptan, 311C90, α-Me-5-HT,BW723C86, and MCPP.
 8. The method of claim 5 wherein the serotoninreceptor agonist is a 5-hydroxytryptamine₁ receptor subtype agonist. 9.The method of claim 5 wherein the serotonin receptor agonist is a5-hydroxytryptamine₂ receptor subtype agonist.
 10. The method of claim 5wherein the effects of the serotonin receptor agonist are exerted in thecentral nervous system.
 11. The method of claim 5 wherein the effects ofthe serotonin receptor antagonist are exerted in the peripheral nervoussystem.
 12. The method of claim 5 wherein the effects of the serotoninreceptor agonist are exerted in the central nervous system and whereinthe effects of the serotonin receptor antagonist are exerted in theperipheral nervous system.
 13. A method of ameliorating a sleep-relatedbreathing disorder comprising administering to a patient in need thereofan effective amount of (a) at least one of a serotonin receptorantagonist (i) in their free base or quaternized form selected from thegroup consisting of hydrodolasetron, mescaline, homochlorcyclizine,perlapine, loxapine, chlorpromazine, haloperidol, desmethylolanzapine,2-hydroxymethylolanzapine,1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime;(ii) and in their quaternized form selected from the group consisting ofondensetron, ketanserin, risperidone, cyproheptadine, clozapine,methysergide, mianserin, ritanserin, cinanserin, LY-53,857, metergoline,LY-278,584, methiothepin, p-NPPL, NAN-190, piperazine, SB-206553,SDZ-205,557, 3-tropanyl-indole-3-carboxylate, and3-tropanyl-indole-3-carboxylate methiodide; and (iii) mixtures thereof;and (b) an effective amount of a selective serotonin reuptake inhibitor.14. The method of claim 13 wherein the selective serotonin reuptakeinhibitor is selected from the group consisting of fluoxetine andparoxetine.
 15. The method of claim 13 wherein the selective serotoninreuptake inhibitor is selected from the group consisting of fluvoxamine,sertraline, citalopram, norfluoxetine, r(−) fluoxetine, s(+) fluoxetine,demethylsertraline, demethylcitalopram, venlafaxine, milnacipran,sibutramine, nefazodone, R-hydroxynefazodone, (−)venlafaxine, and (+)venlafaxine.
 16. A method of ameliorating a sleep-related breathingdisorder comprising administering to a patient in need thereof (a) aneffective amount of at least one serotonin receptor antagonist selectedfrom the group consisting of hydrodolasetron, mescaline,homochlorcyclizine, perlapine, ketanserin, loxapine, chlorpromazine,haloperidol, desmethylolanzapine, 2-hydroxymethylolanzapine,1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime,risperidone, cyproheptadine, clozapine, methysergide, granisetron,mianserin, ritanserin, cinanserin, LY-53,857, metergoline, LY-278,584,methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557,3-tropanyl-indole-3-carboxylate, and 3-tropanyl-indole-3-carboxylatemethiodide; and (b) at least one selective serotonin reuptake inhibitorselected from the group consisting of fluvoxamine, sertraline,fluoxetine, paroxetine, citalopram, norfluoxetine, r(−)fluoxetine,s(+)fluoxetine, demethylsertraline, demethylcitalopram, venlafaxine,minacipran, sibutramine, nefazodone, R-hydroxynefazodone, (−)venlafaxine, and (+)venlafaxine.
 17. A method of ameliorating asleep-related breathing disorder comprising administering to a patientin need thereof an effective amount of at least one serotonin receptorantagonist, in free base or quaternized form, selected from the groupconsisting of cisapride, norcisapride, (+) cisapride, (−) cisapride, (+)norcisapride, and (−) norcisapride.
 18. The method of claim 17 whereinthe sleep-related breathing disorder is selected from the groupconsisting of obstructive sleep apnea syndrome, apnea of prematurity,congenital central hypoventilation syndrome, obesity hypoventilationsyndrome, central sleep apnea syndrome, Cheyne-Stokes respiration, andsnoring.
 19. The method of claim 17 further comprising administering aneffective amount of a selective serotonin reuptake inhibitor selectedfrom the group consisting of fluoxetine, paroxetine, demethylsertraline,demethylcitalopram, venlafaxine, minacipran, sibutramine, nefazodone,R-hydroxynefazodone, (−) venlafaxine, and (+)venlafaxine.